SCHEMBL16463566

SCHEMBL16463566

CC(C)(C)OC(=O)N1CCC(NCc2ccc(F)c([N+](=O)[O-])c2)CC1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.44
DNMT3A Q9Y6K1 1/20 0.43
ALDH1A1 P00352 3/20 0.43
NR1D1 P20393 2/20 0.43
MAPT P10636 2/20 0.42
NPC1 O15118 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
RAB9A P51151 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
LMNA P02545 1/20 0.42
DPP4 P27487 1/20 0.42
EPHX2 P34913 1/20 0.42
TRPV3 Q8NET8 1/20 0.41
PARP1 P09874 1/20 0.41
STS P08842 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17140274 0.92 DNMT3A (0.43) GPR119DNMT3AALDH1A1NR1D1MAPT
SCHEMBL17140268 0.89 ALDH1A1 (0.43) GPR119ALDH1A1NR1D1MAPTNPC1
SCHEMBL17140281 0.88 ALDH1A1 (0.46) GPR119ALDH1A1NR1D1MAPTNPC1
SCHEMBL16463771 0.88 EPHX2 (0.44) GPR119ALDH1A1NR1D1MAPTNPC1
SCHEMBL16463385 0.87 ALDH1A1 (0.47) DNMT3AALDH1A1MAPTNPC1MAPK1
SCHEMBL17140321 0.87 GPR119 (0.43) GPR119DNMT3AALDH1A1NR1D1MAPT
SCHEMBL5012643 0.83 ALDH1A1 (0.58) GPR119ALDH1A1NR1D1MAPTNPC1
SCHEMBL16462077 0.83 EPHX2 (0.47) GPR119DNMT3AALDH1A1MAPTNPC1
SCHEMBL17140249 0.82 ALDH1A1 (0.49) GPR119ALDH1A1MAPTNPC1MAPK1
SCHEMBL16464176 0.82 POLB (0.58) GPR119ALDH1A1MAPTLMNASTS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2906216-B1 INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS KUMAR AJAY (GB) 2020-06-24 EP disclosed
US-9643979-B2 Inhibitors of DNA gyrase for the treatment of bacterial infections VITAS PHARMA RESEARCH PRIVATE LIMITED (IN) 2017-05-09 US disclosed
US-20150284408-A1 INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS KUMAR, AJAY, DR. (GB) 2015-10-08 US disclosed
EP-2906216-A2 INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS Vitas Pharma Research Private Limited (IN) 2015-08-19 EP disclosed
WO-2014057415-A2 INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS VITAS PHARMA RESEARCH PVT LTD (IN) 2014-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284408-A1 INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS TOP1, TOP2A, DNASE1 GPR119 4865/4885DNMT3A 54/4885ALDH1A1 3693/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.